ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

Clinical trial NCT05007873 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05007873
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Phase Chronic Myelogenous Leukemia Philadelphia Chromosome Positive BCR-ABL1 Positive Chronic Myelogenous Leukemia BCR-ABL1 Positive

Start date: 2021-10-21
Primary completion: 2026-10-30
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.